ProCE Banner Activity

CME

Expert Advice on Managing Severe Asthma

Tool
Enter asthma patient characteristics in this online CCO tool and compare your treatment plan with those of 5 experts.

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: August 05, 2020

Expiration: August 04, 2021

No longer available for credit.

Share

Faculty

Michael E. Wechsler

Michael E. Wechsler, MD, MMSc

Professor of Medicine
Director,
NJH Cohen Family Asthma Institute
Division of Pulmonary, Critical Care & Sleep Medicine
National Jewish Hospital
Denver, Colorado

Bradley E. Chipps

Bradley E. Chipps, MDFAAP, FACAAI, FAAAAI, FCCP

President
Medical Director

Capital Allergy & Respiratory Disease Center
Sacramento, California

Nicola Alexander Hanania

Nicola Alexander Hanania, MD, MS

Associate Professor of Medicine
Department of Pulmonary and Critical Care Medicine
Baylor College of Medicine
Houston, Texas

Linda Rogers

Linda Rogers, MD

Associate Professor of Medicine
Mount Sinai National Jewish Health Respiratory Institute
Icahn School of Medicine at Mount Sinai
Clinical Director, Adult Asthma Program
Division of Pulmonary, Critical Care, and Sleep Medicine
Department of Medicine
Mount Sinai Health System
New York, New York

Eileen Wang

Eileen Wang, MD, MPH

Assistant Professor
Division of Allergy and Immunology
Department of Medicine
National Jewish Health
University of Colorado School of Medicine
Denver and Aurora, Colorado

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Novartis Pharmaceuticals Corporation

Sanofi Genzyme and Regeneron Pharmaceuticals

Target Audience

This activity is intended for allergists, immunologists, pulmonologists, primary care physicians, physician assistants, and other healthcare providers who care for patients with severe eosinophilic asthma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select a biologic-based treatment strategy that targets the proinflammatory mechanisms of severe eosinophilic asthma
  • Describe the efficacy and safety of novel targeted biologic agents that have been recently approved as add-on therapy for severe eosinophilic asthma

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Michael E. Wechsler, MD, MMSc

Professor of Medicine
Director,
NJH Cohen Family Asthma Institute
Division of Pulmonary, Critical Care & Sleep Medicine
National Jewish Hospital
Denver, Colorado

Michael E. Wechsler, MD, MMSc, has disclosed that he has received funds for research support from AstraZeneca, Regeneron, Sanofi Genzyme, and Teva and consulting fees from AstraZeneca, Cohero, Equillium, Genentech, GlaxoSmithKline, Novartis, Regeneron, resTORbio, Sanofi Genzyme, and Teva.

Faculty Disclosure

Primary Author

Bradley E. Chipps, MDFAAP, FACAAI, FAAAAI, FCCP

President
Medical Director

Capital Allergy & Respiratory Disease Center
Sacramento, California

Bradley E. Chipps, MDFAAP, FACAAI, FAAAAI, FCCP, has disclosed that he has received consulting fees and fees for non-CME/CE services from AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Novartis, Regeneron, and Sanofi Genzyme.

Nicola Alexander Hanania, MD, MS

Associate Professor of Medicine
Department of Pulmonary and Critical Care Medicine
Baylor College of Medicine
Houston, Texas

Linda Rogers, MD

Associate Professor of Medicine
Mount Sinai National Jewish Health Respiratory Institute
Icahn School of Medicine at Mount Sinai
Clinical Director, Adult Asthma Program
Division of Pulmonary, Critical Care, and Sleep Medicine
Department of Medicine
Mount Sinai Health System
New York, New York

Linda Rogers, MD, has disclosed that she has received funds for research support from AstraZeneca and Sanofi; consulting fees from AstraZeneca, Novartis, and Sanofi; and other financial or material support from AstraZeneca.

Eileen Wang, MD, MPH

Assistant Professor
Division of Allergy and Immunology
Department of Medicine
National Jewish Health
University of Colorado School of Medicine
Denver and Aurora, Colorado

Eileen Wang, MD, MPH, has disclosed that she has received fees for non-CME/CE services from AstraZeneca and funds for research support from Genentech and GlaxoSmithKline.

Staff Disclosure

Staff

Anne Roc, PhD

Director, Scientific Services

Anne Roc, PhD, has no relevant conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSC, ELS, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 05, 2020, through August 04, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this activity is to leverage a point-of-care tool along with expert commentary to improve the competence and performance of learners in diagnosing, assessing, and treating patients with severe eosinophilic asthma.